Replies to post #699947 on NorthWest Biotherapeutics Inc (NWBO)

[Investor082]

I don't come here bitching about them every day unlike some pumpers and bashers who are posting here non stop. I just expressed my views that I don't believe we will go anywhere in terms of share holder return (outside a brief spike) with this management unless they bring large non dilutive cash through big pharma partnership and I have been consistent with that stance.

Part of me thinks a big pharma ought to be waiting in the wings to take on GBM sales at UK approval since there has been no hiring activity and I have mentioned that too. Otherwise, this whole thing stinks! The management has disappointed and dangled enough carrots at the retail over the years.

[OncoJock]

How is it in your interest to encourage anybody else to throw in their hand when you are long?

This is a reasonable question, kabunushi.

I have been keeping my peace on this MB for some time, reluctant to write bad things about a company in which I'm heavily invested, for the very reasons you have mentioned.

I guess what changed recently was reading the Delaware Chancery Court judge's ruling transcript in the packet that was sent earlier this month to all shareholders. Here's what I found on Page 30:

"True-up awards aren't a thing. The term 'true-up' is readily understandable. But there's no suggestion that people who are insiders get to go around trueing themselves up just so they get to keep the same ownership interest in the company. It just doesn't follow. It's straight up self-dealing."

I'm starting to wonder if my best chance at a financial return on my investment is a piece of a class action settlement, since I owned shares at the time the 2022 proxy statement was issued.

-- OJ